$KNSA· SEC filing ·

KNSA Reports $214.3M Q1 Revenue, $22.6M Net Income, Raises 2026 ARCALYST Guidance to $930-945M

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares · PHARMACEUTICAL PREPARATIONS · Now $48.43

+5.7% in 7d after detection

Post-detection moves

1h
1d
-1.6%
3d
+2.6%
7d
+5.7%
30d

Get alerts like this in real time

Push notifications the moment a signal fires. No spam, no crypto, no fluff.

Download for iOS